$1.61 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



NexImmune, Inc is a clinical-stage biotechnology company. The Company is engaged in developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. The Company provides Artificial Immune Modulation (AIM) which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. Its T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The Company’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to lines of therapy, respectively.

Stock Analysis

last close $1.61
1-mo return -29.4%
3-mo return -61.8%
avg daily vol. 237.93T
52-week high 18.78
52-week low 1.51
market cap. $44M
forward pe -
annual div. -
roe -60.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 42%

Subscribe now for daily local and international financial news